November 17, 2020
7 min watch
Save
VIDEO: Odevixibat well tolerated in progressive familial intrahepatic cholestasis
In this exclusive video, Richard Thompson, MD, PhD, discussed results from two abstracts presented at The Liver Meeting Digital Experience on using odevixibat in progressive familial intrahepatic cholestasis.
Thompson, professor of molecular hepatology at King’s College London, reported that odevixibat was well tolerated in the phase 3 extension study. Results showed significant reductions in serum bile acids and pruritus that was maintained up to 48 weeks. He also described the side effect profile as ‘acceptable’.
Published by:
Sources/Disclosures
Collapse
Source:
Thompson R, et al. Efficacy and safety of odevixibat, an ileal bile acid transporter inhibitor, in children with progressive familial intrahepatic cholestasis types 1 and 2: Results from PEDFIC 1, a randomized, double-blind, placebo-controlled phase 3 trial. Presented at: The Liver Meeting Digital Experience; Nov. 13-16, 2020.
Thompson R, et al. LP19. Presented at: The Liver Meeting Digital Experience; Nov. 13-16, 2020.
Thompson R, et al. Efficacy and safety of odevixibat, an ileal bile acid transporter inhibitor, in children with progressive familial intrahepatic cholestasis types 1 and 2: Results from PEDFIC 1, a randomized, double-blind, placebo-controlled phase 3 trial. Presented at: The Liver Meeting Digital Experience; Nov. 13-16, 2020.
Disclosures:
Thompson reports serving on the advisory committee or review panel for Qing Bile Therapeutics and GenerationBio and a consulting for Shire, Albireo, Alexion, GSK, Arcturus, Retrophin, Horizon Pharma, Alnylam, Sana Biotechnology, Mirum, EVOX Therapeutics, Rectify Therapeutics and Qing Therapeutics.
Read more about